High-level marketing copy about this area that is understandable by users who aren’t scientists / are from the general public. Example from Salk - One thing’s for certain: we get older. But the biology of aging is still largely a mystery. As for getting sick as we age - we think that might be optional. At Salk, we are dechiphering the molecular and cellular causes of aging, and searching for ways to stave off Alzheimer’s disease, diabetes, cancer, cardiovascular disease and other age-related ailments. We’re studying how the boyd heals itself, and we’re working on stem-cell technologies that may one day be used to replace organs damaged by injury and disease. They say aging isn’t for the timid, but we think bold science could help people stay healthy as they age.
Infectious disease expert Sunil Ahuja, M.D. earned the prestigious MERIT Award an honor bestowed on less than five percent of NIH-funded researchers.
Dr. Thomas Patterson led one of the largest study sites for the remdesivir COVID-19 clinical trial in the world.
UT Health San Antonio partners with the Vaccine Development Center of San Antonio which fosters research collaborations to promote excellence in vaccine development.
Join us in the fight against COVID-19!
The Novavax clinical trial to evaluate an investigational vaccine is enrolling participants.Take action today; volunteer and play a role in finding a cure.
Additional highlights
Study validates shorter treatment for major world infection, tuberculosis
Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third. Coauthors including Marc Weiner, MD, of The University of Texas Health Science Center at San Antonio, reported the findings May 6 in the New England Journal of Medicine.
Novavax vaccine is highly protective against COVID-19 in Phase 3 results
Researchers at UT Health San Antonio are buoyed by today’s news that the Novavax vaccine is strongly effective against the COVID-19 virus. Biotechnology company Novavax released Phase 3 clinical trial results from 119 sites in the U.S. and Mexico this morning (June 14).
HIV research yields potential drug target
Humans possess a formidable multi-layered defense system that protects us against viral infections. Better understanding of these defenses and the tricks that viruses use to evade them could open novel avenues for treating viral infections and possibly other diseases.